Brandenburg Kapital - News about Adrenomed AG
Adrenomed Supervisory Board Appoints Wolfgang Baiker as CEO
Potsdam - Januar 2021. The whole Adrenomed Team welcomes Dr. Wolfgang Baiker, appointed as new Chief Executive Officer of Adrenomed effective January 1, 2021. Dr. Baiker brings over 30 years of experience in the pharmaceutical and biotechnology industry and until retirement served as President and CEO of Boehringer Ingelheim USA. Together with Dr. Baiker, Adrenomed looks forward to advancing the development of Adrecizumab, an urgently needed therapeutic to treat septic shock.
Brandenburg Kapital GmbH has been supporting the company since 2014.
Read the complete press release int the attached download.
About Adrenomed
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
For further information, please visit www.adrenomed.com and www.brandenburg-kapital.de